pc 버전으로 이동 중 [시장보고서]세계의 바이오의약품 첨가제 시장 동향, 시장 점유율, 시장 규모 예측(2021-2028년) : 제품(폴리올, 가용화제, 계면 활성제/유화제 탄수화물), 지역별
세계의 바이오의약품 첨가제 시장 동향, 시장 점유율, 시장 규모 예측(2021-2028년) : 제품(폴리올, 가용화제, 계면 활성제/유화제 탄수화물), 지역별
Biopharmaceutical Excipients Market Size, Share & Trends Analysis Report By Product (Polyols, Solubilizers & Surfactants/Emulsifiers, Carbohydrates), By Region, And Segment Forecasts, 2021 - 2028
상품코드 : 995261
리서치사 : Grand View Research, Inc.
발행일 : 2021년 02월
페이지 정보 : 영문 150 Pages
US $ 5,950 ₩ 7,404,000
Unprintable PDF (Single User License)
US $ 6,950 ₩ 8,648,000
Printable PDF (5-User License)
US $ 8,950 ₩ 11,137,000
Printable PDF (Enterprise License)


한글목차

세계의 바이오의약품 첨가제 시장 규모는 예측 기간 동안 6.5%의 CAGR로 2028년 34억 달러 규모로 성장할 것으로 예측됩니다.

바이오시밀러 개발 증가, 약물 및 백신 불안정, 신약 개발에 대한 초점 확대 등의 요인이 시장 성장을 추진하고 있습니다.

세계의 바이오의약품 첨가제(Biopharmaceutical Excipients) 시장을 조사했으며 시장 정의 및 개요, 코로나19(COVID-19) 및 기타 시장 영향 요인 분석, 시장 규모 추이·예측, 제품·지역/주요국 등 각종 구분별 분석, 경쟁 환경, 주요 기업 개요 등을 정리하여 전해드립니다.

제1장 개요

제2장 조사 방법·조사 범위

제3장 시장 변수·동향·전망

제4장 시장 예측·동향 분석 : 제품별

제5장 시장 예측·동향 분석 : 지역 및 주요 국가별

제6장 경쟁 상황

NJH 21.03.19
영문 목차

영문목차

Biopharmaceutical Excipients Market Growth & Trends

The global biopharmaceutical excipients market size is expected to reach USD 3.4 billion by 2028, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 6.5% from 2021 to 2028. The factors driving the market growth include increasing development of biosimilars, instability associated with drugs & vaccines, and growing focus on the development of novel drugs, among others.

The changing regulatory scenarios by both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have impacted drug development. Several legislative proposals are addressing new ways for lowering the cost of prescription drugs. Similarly, in recent years there is an increasing focus on drug-manufacturing quality has led to several recalls by FDA and the EMA. Hence, the stringent investigations related to an examination of drugs are likely to promote the use of specific excipients for developing efficient drugs.

In addition, companies are collaborating with government authorities for increasing the application of novel compounds. For instance, in December 2019, U.S. FDA started a pilot program to evaluate novel biopharmaceutical excipients. Later, the initiative was supported by several companies such as AstraZeneca, Regeneron, and Janssen for FDA's plan to review novel biopharmaceutical excipients. Regeneron highlighted different novel compounds that can potentially help in improving public health for example hydrophobic salts can reduce the viscosity of highly concentrated antibody formulations.

Moreover, the rising focus on the rapid development of COVID-19 vaccines and therapeutic drugs is further driving the market growth. Excipients have an essential role in the development of biologics as it helps in stabilizing the drug during storage and processing. The use of appropriate biopharmaceutical excipients enables the development of novel therapies and robust pharmaceutical products for fighting against the pandemic.

Large-scale pharmaceutical companies signed a long-term supply agreement with companies for supporting the development of COVID-19 vaccines. For instance, in November 2020, Pfizer Inc. signed a five-year contract with Croda International for lipid-based excipients that will be used for manufacturing Pfizer's COVID-19 vaccine candidate. Similarly, in May 2020, Moderna signed a supply agreement with CordenPharma for the large-scale production of lipid excipient for the development of mRNA-1273, Moderna's COVID-19 vaccine candidate.

Biopharmaceutical Excipients Market Report Highlights

Carbohydrates accounted for the largest revenue share of 36.2% in 2020 owing to the increasing use of carbohydrates owing to their several advantages

The advantages include it helps the efficient binding of tablet ingredients, enables accurate dosing and protecting the tablet from harsh environmental conditions, among others

Sucrose amongst the carbohydrates dominated with a market share of 32.8% owing to its increasing application in stabilizing proteins

Starch is expected to witness the fastest CAGR of 6.6% from 2021 to 2028 owing to the increasing launch of new starch excipients

For instance, in May 2019, Colorcon Inc. launched STARTAB, a new starch tableting excipient. It is developed by directly compressible starch for enhancing the stability of moisture sensitive API

North America has emerged as the highest revenue-generating region, representing a market share of 32.0% in 2020

Large pharmaceutical companies are entering in collaboration with the companies in the region which can be attributed to market growth

For instance, in February 2020, MilliporeSigma entered in an agreement with ReForm Biologics LLC for commercializing ReForm's excipients that are used in biotherapeutic formulations

In Asia Pacific, the market is expected to witness a lucrative CAGR of 7.0% from 2021 to 2028 owing to the increasing production of biosimilar drugs in the region

The government in this region is promoting biosimilar development. For instance, the government of South Korea provided regulatory guidance to local biosimilars companies for aiming to develop around 22.0% of global biosimilars by 2020

Table of Contents

Chapter 1 Executive Summary

Chapter 2 Methodology and Scope

Chapter 3 Market Variables, Trends & Scope

Chapter 4 Market Categorization: Product Estimates & Trend Analysis

Chapter 5 Market Categorization: Regional Estimates & Trend Analysis, by Product

Chapter 6 Competitive Landscape

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기